Jaguar Health Receives Additional $3 Million Payment from Future Pak

Jaguar Health, Inc. announced a $3 million payment from Future Pak, LLC. This follows the termination of Jaguar's buy-back provision in their January 2026 U.S. licensing agreement for Mytesi and Canalevia-CA1. The agreement granted Future Pak exclusive marketing rights for these crofelemer-based drugs. Jaguar concentrates its efforts on human rare-disease indications and continues to manufacture Mytesi and Canalevia-CA1 for Future Pak.

Initial payments included $16 million, with the possibility of an additional $20 million in milestone payments. The focus remains on crofelemer's potential for treating rare intestinal disorders. Multiple studies are ongoing, and the company anticipates filing an NDA with the FDA by mid-2027.